Now showing items 1-5 of 5
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
(Journal of Clinical Oncology, 2019-04-20)
PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC). We ...
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
(Blood Cancer Journal, 2019-03-29)
This phase I dose-escalation/expansion study evaluated isatuximab (anti-CD38 monoclonal antibody) monotherapy in patients with relapsed/refractory multiple myeloma (RRMM). Patients progressing on or after standard therapy ...
Operative vs Nonoperative Treatment for Atraumatic Rotator Cuff Tears A Trial Protocol for the Arthroscopic Rotator Cuff Pragmatic Randomized Clinical Trial
(JAMA Networks Open, 2019-08)
IMPORTANCE Rotator cuff disorders remain the most common cause of shoulder pain and are among the most common reasons for patients to seek care in primary and specialty settings. Although operative and nonoperative treatments ...
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study
(JCO Precision Oncology, 2019-06-27)
PURPOSE To study whether BRAF V600 mutations in non-small-cell lung cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor vemurafenib, we included a cohort of patients with NSCLC in the vemurafenib basket (VE-BASKET) ...
Recovery of Motor Function after Mixed and Motor Nerve Repair with Processed Nerve Allograft
(Plastic and Reconstructive Surgery-Global OPEN, 2019-03)
Background : Severe trauma often results in the transection of major peripheral nerves. The RANGER Registry is an ongoing observational study on the use and outcomes of processed nerve allografts (PNAs; Avance Nerve Graft, ...